Tostran testosterone: Phase IIIb/IV data

In the Phase IIIb/IV TIMES 2 trial, Tostran met the primary endpoint of a significant improvement in insulin sensitivity vs. placebo after 6 and 12 months (p=0.05 and p=0.01, respectively). The compou...